Black Diamond Therapeutics, Inc. is a precision oncology medicine company dedicated to developing targeted therapies for genetically defined cancers.
It specifically targets oncogenes that are activated by allosteric mutations, known as MasterKey mutations. By focusing on these specific mutations, the company aims to develop more effective and selective cancer treatments. Their research involves identifying and understanding unique mutation patterns that drive cancer growth, allowing for the design of drugs that can block these cancer-promoting processes. This targeted approach helps in potentially offering patients therapies with fewer side effects compared to traditional cancer treatments.
